First Patient Dosed in Australia in ATG-101 First-in-Human Trial
- Written by PR Newswire
Study to evaluate ATG-101, a proprietary PD-L1/4-1BB bispecific antibody
Study will enroll patients with Metastatic/Advanced Solid Tumors and Mature B-Cell Non-Hodgkin Lymphomas
 |
SHANGHAI AND HONG KONG, Dec. 20, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative global biopharmaceutical company...
